Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

The total amount Novavax will pay depends on whether Gavi decides to order more Covid shots from the cash-strapped company over the next five years.

Novavax to settle dispute over canceled Covid vaccine purchase agreement

Pfizer

Novavax is making progress along the path to recovery -- and its combined COVID/flu vaccine candidate could drive growth. Pfizer offers better growth prospects than you might think, as well as a juicy dividend.

Better Bull Market Buy: Novavax vs. Pfizer

Novavax said on Thursday it has agreed to pay back international vaccine group Gavi at least $475 million in cash or vaccines by the end of 2028, settling a dispute over canceled orders that had created financial uncertainty for the U.S. maker of COVID-19 shots.

Novavax settles dispute with international vaccine group Gavi

GAITHERSBURG, Md. and GENEVA , Feb. 22, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) and Gavi, the Vaccine Alliance (Gavi) today announced they have reached a settlement related to the 2021 Advance Purchase Agreement (APA) for Novavax's prototype COVID-19 vaccine (NVX-CoV2373).

Novavax and Gavi Reach Settlement on 2021 COVID-19 Vaccine Advance Purchase Agreement

Incyte

Cassava Sciences Inc

The unpredictability of the biotech sector, highlights the inherent risks involved in certain biotech stocks to sell. 2023 was a rough year for the market, marked by a 10% plunge in the SPDR S&P Biotech ETF (XBI), alongside widespread layoffs and fundraising challenges.

Exit Now! 3 Biotech Stocks to Sell in February 2024

GAITHERSBURG, Md. , Feb. 20, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its fourth quarter and full year 2023 financial results and operational highlights at 8:30 a.m.

Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights on February 28, 2024

After commercializing its first vaccine, Novavax is sputtering as it looks for a follow-up. Its pipeline is looking very thin, and it's being forced to scale down its operations.

Where Will Novavax Be in 10 Years?

Moderna

Maravai LifeSciences Holdings

The unpredictable nature of the biotech industry, which frequently flirts with failure, underscores the inherent risks and rewards associated with doomed biotech stocks. The journey from drug discovery to market approval is notoriously long and uncertain.

3 Doomed Biotech Stocks to Dump Before They Dive: February 2024

Chewy

Toast

Toast is growing revenue and payment volume in the double digits. Chewy is expanding into Canada, which could become a significant market for the e-commerce company.

3 Beaten-Down Growth Stocks that Could Take off in the New Bull Market

Teladoc

Novavax missed out on the biggest opportunity for COVID-19 vaccine revenue, but its investigational covid/flu vaccine may offer it future growth potential. Teladoc Health has put the focus on balancing revenue growth with its quest for profitability, and its efforts are bearing fruit.

Better Recovery Story Buy: Novavax vs. Teladoc

Novavax stock surely made millionaires in the past as it rose more than 2,700% back in 2020. Today, the stock has fallen more than 90% from its peak as the company faces various challenges.

Could Novavax Stock Help You Become a Millionaire?

Biotechnology firm Novavax (NASDAQ: NVAX )– which specializes in developing and commercializing next-generation vaccines — just announced a fresh round of job cuts. Earlier today, management said that it would reduce its global staff by about 12%.

Novavax Layoffs 2024: What to Know About the Latest NVAX Job Cuts

Vaccine maker Novavax said on Wednesday it will reduce its total global workforce by about 12% as part of its ongoing efforts to reduce costs.

Novavax to cut 12% of global workforce

Lexicon Pharmaceuticals

Plug Power

Pockets of optimism can always be found among Wall Street analysts. Three off-the-radar stocks could deliver jaw-dropping gains in 2024, based on the high-water price targets of three analysts.

3 Under-the-Radar Stocks With 340% to 762% Upside in 2024, According to Select Wall Street Analysts

Novavax's coronavirus vaccine may be more effective than others. But there isn't much demand anymore, and the biotech's overhead is high.

1 Reason to Buy Novavax Stock, and 3 (Better) Reasons to Sell

Novavax shares soared earlier in the pandemic, but they've dropped 98% from their peak. The company faces challenges, but it still could win over time in the post-pandemic vaccine market.

1 Reason to Buy Novavax Stock Hand Over Fist and 1 Reason to Sell

Novavax stock remains under pressure despite winning a key designation for its malaria shot. Is NVAX stock a buy or a sell in January 2024?

Is Novavax Stock A Buy After Winning A Key Designation From The World Health Organization?

Novavax was an early pandemic success story, surging more than 2,000% as investors bet on its coronavirus vaccine. But when the vaccine fell behind, the stock tumbled and hasn't yet recovered.

Novavax Stock May Soar 379%, According to Wall Street. Is the Stock a Buy Right Now?

GameStop

Lucid Group

One secret to making money in the markets is to keep holding winners and exit the losers as soon as a red flag appears. Investors need to keep aside biases and ego if the target is to make wealth from the markets.

Are You Kidding Me? 3 Meme Stocks You Should Have Already Sold

AMC Entertainment

Following last year's big rally, the stock market is off to a slow start in 2024. After two weeks the S&P 500 index is essentially flat.

Time to Buy These 3 Stocks That Just Hit a 52-Week Low?

Novavax, Inc. (NVAX) CEO John Jacobs Presents at JPMorgan 42nd Annual Healthcare Conference Transcript

JD.com

Petco Health and Wellness

Wall Street delivered a banner year in 2023, with the Dow hitting an all-time high and the Nasdaq Composite surging 43%. Despite big gains for the broader market, some high-flying stocks remain well below their peaks.

3 Turnaround Stocks With 151% to 600% Upside in 2024, According to Select Wall Street Analysts

GAITHERSBURG, Md. , Jan. 3, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it will participate in the 42th Annual J.P.

Novavax to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Fastly

Fiverr

Match Group

Pubmatic

StoneCo

Wall Street produced stellar gains in 2023, with the growth-focused Nasdaq Composite rallying 43%. This year is shaping up to be a stock picker's market.

7 Magnificent Stocks That Can Double Your Money in 2024

C3.ai

Biomea Fusion Inc

Beyond Meat

Carvana

Fisker Inc

B. Riley Financial

Trupanion

Frontier Group Holdings

Upstart Holdings

The number of shorted shares has grown 23% since the end of 2020, but that doesn't mean traders are getting more bearish about the market.

News for Novavax Stock (NVAX)